Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG has launched an observational study titled ‘OASIS PoST-Trial PAtient Registry (OASIS STAR)’ to investigate the burden of vasomotor symptoms (VMS) and treatment patterns in menopausal women before and after their participation in OASIS studies. The study aims to gather real-world data on prescription trends and healthcare resource utilization, focusing on the impact of the drug elizanetant, which has been previously assessed in OASIS trials.
The study does not involve any new interventions, as it solely collects observational data from participants who have already received standard care for VMS. The main focus is on understanding treatment patterns and the continuation or cessation of medications.
Designed as a prospective cohort study, it will collect data through online surveys and anonymized medical records, ensuring participant privacy. The study is being conducted electronically, without requiring any additional visits or tests.
The study began on April 30, 2025, with data collection for Part A scheduled between March and June 2025, and Part B between April and May 2025. The last update was submitted on July 25, 2025, indicating ongoing recruitment.
This study could potentially influence Bayer’s stock performance by providing insights into the real-world effectiveness of elizanetant, potentially strengthening its market position against competitors. Investors should monitor updates for any significant findings that could impact Bayer’s market strategy.
The study is currently recruiting, with further details available on the ClinicalTrials portal.